Ventfort Research Overview (also known as A-3 vascular peptide complex, Blood-vessel peptide bioregulator, Ventfort A-3, Cytomax A-3)
A vascular peptide bioregulator (Cytomax A-3) containing low-molecular peptides isolated from bovine aortic tissue. Studied for improving vascular wall metabolism, normalizing blood lipid profiles, supporting microcirculation, and reducing age-related vascular fragility. Used in Khavinson longevity protocols as the cardiovascular stack component.
What Is Ventfort?
Ventfort is a vascular-specific peptide bioregulator containing a complex of low-molecular-weight peptides (≤10,000 Da) isolated from the aortic tissue of young calves (≤12 months). Developed within the Khavinson Cytomax system at the St. Petersburg Institute of Bioregulation and Gerontology, it is studied for its ability to normalize metabolism and structure in blood-vessel wall cells, improve microcirculation, regulate blood lipids, and support arterial and venous health — with reported benefits in atherosclerosis, microcirculation disorders, senile purpura, and age-related vascular fragility. It is marketed as a biologically active food additive (dietary supplement) rather than a conventional pharmaceutical.
Research Background
Ventfort belongs to the Khavinson Cytomax class of organ-derived peptide bioregulators — short peptide complexes extracted from specific tissues to restore tissue-specific gene expression patterns and cellular function. The A-3 peptide complex is isolated from bovine aortic tissue using a proprietary extraction and purification process. Experimental work at the St. Petersburg Institute demonstrated tissue-specific action on vascular wall cells, improving trophism and metabolism. Clinical studies in patients with arterial atherosclerosis and senile purpura confirmed favorable impact on vascular health, microcirculation, and blood lipid profiles — supporting its use as a medical-preventive adjunct and longevity vascular tool.
Mechanism of Action
Ventfort's proposed mechanisms center on tissue-specific epigenetic modulation. As a natural peptide complex (not a single synthetic peptide), it is thought to interact with vascular wall cell DNA to restore normal gene expression patterns — normalizing connexin expression, endothelial metabolism, stress resistance, and angiogenic pathways. A documented secondary mechanism is lipid regulation: clinical data show reduction in blood cholesterol and atherogenic lipoprotein levels in atherosclerosis subjects. Effects build gradually over a 10–30-day course and persist for months via structural vascular remodeling rather than sustained plasma levels — the peptide itself clears rapidly, but its downstream gene-expression and structural changes are durable.
Quick Reference
| Literature-Reported Dose Range | 2 capsules (20 mg/day) — intensive; 10 mg/day maintenance |
| Literature-Reported Frequency | Once or twice daily, taken 10–15 min before meals |
| Course Length | 10–30 days (intensive); 10 days (maintenance) |
| Routes | Oral (capsules) · Sublingual (lingual drops, 10 mg/mL) |
| Cycle Pattern | On 10–30 days → Off 3–6 months; repeat as needed |
Research Indications
Atherosclerosis & Vascular Disease
Arterial Atherosclerosis
IAS clinical study in patients with arterial atherosclerosis demonstrated improved general health, better vascular wall condition (normalization of functional and morphological changes), and regulated blood cholesterol and lipoprotein levels — reducing atherogenic lipoproteins and decreasing risk of vascular defects.
Lipid Regulation
Ventfort reduces blood cholesterol and atherogenic lipoprotein levels in atherosclerosis subjects, contributing to decreased plaque formation risk. Modern commentaries extend this to conceptual anti-plaque and vascular-damage-repair roles via selective gene regulation in vascular wall cells.
Microcirculation & Senile Purpura
Senile Purpura (Age-Related Vascular Fragility)
In elderly patients with senile purpura (subcutaneous bleeding from fragile capillaries), Ventfort courses of 10–30 days improved vascular wall function, microcirculation, and reduced purpura manifestations. Recommended for elderly maintenance of vascular system function.
Microcirculation Disorders
Ventfort is studied for improvement of peripheral microcirculation in affected tissues, with application in age-related small-vessel pathology and microvascular insufficiency.
Peripheral & Cerebral Vascular Conditions
Peripheral Vascular Disease
Conceptual application to atherosclerosis of lower-limb vessels, obliterating endarteritis, intermittent claudication, varicose veins, hemorrhoids, and thrombophlebitis — extrapolated from vascular wall mechanism and lipid-regulation data rather than direct RCTs.
Cerebral Circulation
Product descriptions list cerebral atherosclerosis and cerebral circulation disorders as application areas based on the tissue-specific vascular wall mechanism. Direct evidence in cerebrovascular conditions is limited.
Hypertension & Coronary Health
Arterial hypertension, coronary heart disease, and angiopathy of various genesis are listed as conceptual use areas. Evidence is extrapolated from the vascular epigenetic model; not confirmed by large independent trials.
Cardiovascular Aging & Longevity
Anti-Aging Vascular Protocol
Within the Khavinson longevity framework, Ventfort is a first-class vascular bioregulator used in multi-organ aging protocols — often combined with Cardiogen (heart) and other organ-specific peptides to address systemic vascular aging and maintain vascular tissue gene expression patterns.
Angiogenesis & Endothelial Repair
Vascular peptide data suggest Ventfort promotes angiogenesis and endothelial repair, improving tissue perfusion and systemic resilience. Most data are cell/animal-level; human endothelial repair evidence is preliminary.
Research Protocols
Educational reference only — not medical dosing guidance
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Atherosclerosis / macrovascular | 1–3 caps (10–30 mg) | 2–3× daily · 10–20 days | Oral |
| Senile purpura / microcirculation | 1–3 caps (10–30 mg) | 2–3× daily · 10–30 days | Oral |
| Intensive vascular repair (modern) | 2 caps (20 mg) | Once daily · 30 days | Oral |
| Maintenance (every 3–6 months) | 2 caps (20 mg) | Once daily · 10 days | Oral |
| Higher-need monthly maintenance | 2 caps (20 mg) | Once daily · 10 days/month | Oral |
| Lingual vascular support | ~10 mg (5–6 drops) | Once daily · 1–3 months | Sublingual |
Peptide Interactions
Both are vascular bioregulators but with different targets: Vesugen is a synthetic tripeptide (Lys-Glu-Asp) acting primarily on endothelial cells and erectile/micro-vascular function; Ventfort is a natural aortic peptide complex with broader vascular wall and lipid-regulatory action. Used together for comprehensive vascular coverage in longevity protocols — select based on primary target.
Commonly combined with Pielotax to improve renal microcirculation and nutrient delivery, supporting kidney repair and detox alongside systemic vascular support. Standard Khavinson multi-organ stack pairing; no reported adverse interactions.
Ventfort is the vascular component of Khavinson's first-class longevity stack. Frequently combined with Cardiogen (heart), and other organ-specific Cytomax peptides for multi-system aging protocols. Each peptide complex acts tissue-specifically, so combination is considered safe and complementary by design.
Ventfort was used adjunctively in clinical atherosclerosis therapy alongside conventional symptomatic and pathogenetic treatments. No major interactions or contraindications were reported in the IAS clinical study. Functions as a complementary biologically active food additive, not a drug requiring pharmacokinetic interaction monitoring.
Reported Research Timeline
01Days 1–10 (first course) (reported in cited studies): Patients with atherosclerosis and senile purpura report improved general well-being, early vascular wall normalization, and initial improvements in microcirculation in affected tissues. Lipid profile changes begin but may not yet be measurable.
02Days 10–30 (completing intensive course) (reported in cited studies): Vascular wall function continues to improve; blood cholesterol and atherogenic lipoprotein levels normalize. Symptoms related to poor circulation — cold extremities, easy bruising, some varicose complaints — may begin to lessen. Effects build gradually rather than acutely.
03Post-course (1–3 months off): Epigenetic and structural changes in vascular wall cells persist well beyond the dosing period. Microcirculation, lipid regulation, and vascular wall integrity remain improved without continued dosing, supporting the 3–6-month interval between courses.
04Repeat course (every 3–6 months): Each subsequent course reinforces and extends vascular remodeling effects. Long-term Khavinson protocols describe cumulative structural rejuvenation of blood-vessel walls with multi-year use. Higher-need individuals may benefit from monthly 10-day maintenance cycles.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Well tolerated at recommended doses in published clinical studies. The IAS report states no side effects and no contraindications were observed at oral administration in atherosclerosis and senile purpura patients.
Derived from bovine (young calf) aortic tissue. Individuals with hypersensitivity to beef proteins or bovine-derived ingredients should exercise caution and consult before use.
Evidence base is primarily Russian clinical and experimental studies — generally small, non-randomized, and short-term. Data are not replicated in large Western RCTs. Mechanism and gene-regulatory actions are promising but not fully elucidated; PubMed indexes only ~30 studies on vascular bioregulators over several decades.
Not an approved pharmaceutical drug. Marketed as a biologically active food additive / dietary supplement. Regulatory status varies by country; not subject to the same safety and efficacy evaluation as approved medicines.
Courses are short (10–30 days) followed by long off-periods (3–6 months) — continuous daily use is not the intended protocol and has not been evaluated for long-term safety.
Stop Use / Red Flag: Product does not explicitly identify peptide complex A-3 (aorta/blood-vessel peptides) or lacks any Khavinson-licensed or third-party verification of vascular peptide origin.
Seek Medical Attention If:
Persistent injection site reactions (redness, pain, or swelling beyond 48 hours)
Signs of allergic reaction (hives, difficulty breathing, or facial swelling)
Severe or unusual symptoms following administration
Always consult a licensed physician before and during use
Quality Indicators
Verified Marker
Peptide Complex A-3 Clearly Labeled
Product label explicitly lists peptide complex A-3 (aorta/blood-vessel peptides) at 10 mg per capsule. Capsule form should clearly identify aortic tissue origin.
Verified Marker
Lingual Concentration Specified
Lingual (sublingual) products explicitly state 10 mg A-3 per 1 mL (~5–6 drops). Unlabeled concentrations or missing per-drop dosing information are a yellow flag.
Verified Marker
Khavinson Institute–Associated Manufacturing
Manufactured under technology associated with the St. Petersburg Institute of Bioregulation and Gerontology, or licensed from the Khavinson technology base. Look for Cytomax A-3 designation or Institute acknowledgment on packaging.
Quality Concern
No A-3 Identification or Third-Party Verification
Products that do not explicitly identify peptide complex A-3 or do not provide third-party laboratory verification of vascular peptide content should be avoided. The peptide complex designation is the primary quality marker.
Quality Concern
Unclear Origin or Inadequate Content Labeling
Inadequate labeling of peptide content per capsule or per drop, or unclear origin of the vascular peptide source, indicates a product that cannot be verified against the Khavinson clinical data.
Research Citations
Ventfort / A-3 vascular peptide bioregulator research originates primarily from the St. Petersburg Institute of Bioregulation and Gerontology. PubMed indexes approximately 30 studies on vascular Cytomax bioregulators over several decades. Key source types include:
- Khavinson VKh et al. — Experimental studies on tissue-specific peptide complexes (organ-derived bioregulators) demonstrating selective action on isolated tissue cell types, improved trophism, and normalized functional/morphological changes.
- IAS (International Aging Systems) clinical summary — Double-blind controlled study in patients with arterial atherosclerosis and senile purpura; documented improvements in vascular wall condition, microcirculation, and blood lipid profiles; reported good tolerability with no adverse effects.
- Khavinson VKh — Peptides and Aging (monograph); Khavinson VKh, Anisimov VN — Geroprotective effects of epithalamine and other peptide bioregulators (Gerontology reviews).
- SeekPeptides / modern longevity review literature — Commentary on epigenetic / connexin-normalization mechanisms and Cytomax stack design; not primary clinical data.
Note: Large-scale independent RCTs validating Ventfort are not yet available. The evidence base is preliminary and the above citations reflect the full scope of available data.
Research Focus
Vascular health, Endothelial function, Anti-aging, Blood vessel restoration, Cardiovascular health
Frequently Asked Questions
What should researchers watch for with Ventfort?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Ventfort?
Days 1–10 (first course) (reported in cited studies): Patients with atherosclerosis and senile purpura report improved general well-being, early vascular wall normalization, and initial improvements in microcirculation in affected tissues. Lipid profile changes begin but may not yet be measurable.
How is Ventfort typically administered in research?
Educational reference only — not medical dosing guidance
Browse all peptides in the Encyclopedia →